---
title: "Stelara (ustekinumab) in plaque psoriasis: Clinical trials questions"
description: "Clinical trials questions on Stelara (ustekinumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Subgroup results, Maintenance of response, and Pediatric efficacy. Questions: How were the Stelara adult plaque psoriasis trials designed? Who was enrolled in the Stelara adult plaque psoriasis trials? How effective is Stelara for plaque psoriasis at 12 weeks (PHOENIX 1 and 2)? How many patients reached PASI 90 on Stelara at Week 12 (PHOENIX 2)? 3 further questions follow. 7 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/clinical-trials"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Stelara (ustekinumab) in plaque psoriasis: Clinical trials questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Stelara](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf)

Questions that apply to every indication of Stelara are on [Stelara (ustekinumab), all indications](https://www.evicenter.com/medical-information/stelara).

## Clinical trials

<a id="stelara-adult-trial-design"></a>

### How were the Stelara adult plaque psoriasis trials designed?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “Two multicenter, randomized, double-blind, placebo-controlled trials (Ps STUDY 1 
> and Ps STUDY 2) enrolled a total of 1996 subjects 18 years of age and older with 
> plaque psoriasis who had a minimum body surface area involvement of 10%, and 
> Psoriasis Area and Severity Index (PASI) score ≥12, and who were candidates 
> for phototherapy or systemic therapy. Subjects with guttate, erythrodermic, or 
> pustular psoriasis were excluded from the trials.
> Ps STUDY 1 enrolled 766 subjects and Ps STUDY 2 enrolled 1230 subjects. The trials 
> had the same design through Week 28. In both trials, subjects were randomized 
> in equal proportion to placebo, 45 mg or 90 mg of STELARA. Subjects randomized 
> to STELARA received 45 mg or 90 mg doses, regardless of weight, at Weeks 0, 4, 
> and 16. Subjects randomized to receive placebo at Weeks 0 and 4 crossed over to 
> receive STELARA (either 45 mg or 90 mg) at Weeks 12 and 16.”

Source: [STELARA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=8)

> “In both trials, the endpoints were the proportion of subjects who achieved at least 
> a 75% reduction in PASI score (PASI 75) from baseline to Week 12 and treatment 
> success (cleared or minimal) on the PGA. The PGA is a 6-category scale ranging 
> from 0 (cleared) to 5 (severe) that indicates the physician’s overall assessment of 
> psoriasis focusing on plaque thickness/induration, erythema, and scaling.”

Source: [STELARA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=8)

<a id="stelara-adult-trial-population"></a>

### Who was enrolled in the Stelara adult plaque psoriasis trials?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “In both trials, subjects in all treatment groups had a median baseline PASI score 
> ranging from approximately 17 to 18. Baseline Physician’s Global Assessment 
> (PGA) score was marked or severe in 44% of subjects in Ps STUDY 1 and 40% of 
> subjects in Ps STUDY 2. Approximately two-thirds of all subjects had received prior 
> phototherapy, 69% had received either prior conventional systemic or biologic 
> therapy for the treatment of psoriasis, with 56% receiving prior conventional 
> systemic therapy and 43% receiving prior biologic therapy. A total of 28% of 
> subjects had a history of psoriatic arthritis.”

Source: [STELARA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=8)

## Study results

<a id="stelara-week-12-results"></a>

### How effective is Stelara for plaque psoriasis at 12 weeks (PHOENIX 1 and 2)?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “IN PHOENIX 1:
> PGA 0/1 was a major secondary endpoint at Week 12, and was achieved by nearly 6 of 10 patients in the 45-mg and 90-mg groups (59% [151/255] and 61% [156/256], respectively) compared with 4% (10/255) in the placebo group.<sup>1,2</sup>
> IN PHOENIX 2:
> The primary endpoint was PASI 75 at Week 12 (45 mg: 67% [273/409]; 90 mg: 76% [311/411]; placebo: 4% [15/410]; P<0.0001 vs placebo for each dose).<sup>1,3</sup>
> PGA 0/1 was a major secondary endpoint at Week 12, and was achieved by 7 of 10 patients in the 45-mg and 90-mg groups (68% [277/409] and 73% [300/411], respectively) compared with 4% (18/410) in the placebo group (P<0.0001 vs placebo for each dose).<sup>1,3</sup>”

Source: [STELARA: STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/efficacy/#:~:text=IN%20PHOENIX%201%3A,%28P%3C0.0001%20vs%20placebo%20for%20each)

> “PASI=Psoriasis Area and Severity Index; PGA=Physician's Global Assessment; PGA 0/1=Proportion of patients who achieved a PGA score of cleared (0) or minimal (1) using a 5-point scale: cleared (0), minimal (1), mild (2), moderate (3), marked (4), and severe (5).”

Source: [STELARA: STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/efficacy/#:~:text=PASI%3DPsoriasis%20Area%20and%20Severity%20Index%3B,marked%20%284%29%2C%20and%20severe%20%285%29.)

> “<sup>*</sup>PASI 75 responder was defined as patients with greater than or equal to 75% improvement in PASI from baseline.”

Source: [STELARA: STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/efficacy/#:~:text=75%20responder%20was%20defined%20as,improvement%20in%20PASI%20from%20baseline.)

> “Table 12: Clinical Outcomes at Week 12 in Adult Subjects with Plaque Psoriasis 
> in Ps STUDY 1 and Ps STUDY 2 
> Ps STUDY 1
> Ps STUDY 2
> STELARA
> STELARA
> Placebo
> 45 mg
> 90 mg
> Placebo
> 45 mg
> 90 mg
> Subjects randomized
> 255
> 255
> 256
> 410
> 409
> 411
> PASI 75 response
> 8 (3%)
> 171 (67%) 170 (66%) 15 (4%) 273 (67%) 311 (76%)
> PGA of Cleared or 
> Minimal
> 10 (4%) 151 (59%) 156 (61%) 18 (4%) 277 (68%) 300 (73%)”

Source: [STELARA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=8)

Note: The prescribing information reports the adult trials as Ps STUDY 1 and Ps STUDY 2; its Week 12 counts match those the HCP site gives for PHOENIX 1 and PHOENIX 2. Table 12 columns are placebo, STELARA 45 mg, and STELARA 90 mg for each trial.

<a id="stelara-pasi-90"></a>

### How many patients reached PASI 90 on Stelara at Week 12 (PHOENIX 2)?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “IN PHOENIX 2:
> At Week 12, PASI 90 was 42% (173/409) and 51% (209/411) in patients taking STELARA<sup>®</sup> 45 mg and 90 mg, respectively, vs 1% (3/410) of patients taking placebo.<sup>1,3</sup>”

Source: [STELARA: STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/efficacy/#:~:text=IN%20PHOENIX%202%3A,1%25%20%283%2F410%29%20of%20patients%20taking)

On the page, select: PASI 90

> “<sup>*</sup>PASI 90 is a prespecified analysis that was not adjusted for multiplicity; statistical significance has not been established.”

Source: [STELARA: STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/efficacy/#:~:text=90%20is%20a%20prespecified%20analysis,significance%20has%20not%20been%20established.)

On the page, select: PASI 90

> “<sup>†</sup>PASI 90 responder was defined as patients with greater than or equal to 90% improvement in PASI from baseline.”

Source: [STELARA: STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/efficacy/#:~:text=90%20responder%20was%20defined%20as,improvement%20in%20PASI%20from%20baseline.)

On the page, select: PASI 90

## Subgroup results

<a id="stelara-efficacy-by-weight"></a>

### Does Stelara work as well in patients over 100 kg?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “In subjects who weighed 100 kg or less, response rates were comparable with 
> both the 45 mg and 90 mg doses; however, in subjects who weighed greater than 
> 100 kg, higher response rates were seen with 90 mg dosing compared with 45 mg 
> dosing (Table 13 below).
> Table 13: Clinical Outcomes by Weight at Week 12 in Adult Subjects with Plaque 
> Psoriasis in Ps STUDY 1 and Ps STUDY 2
> Ps STUDY 1
> Ps STUDY 2
> STELARA
> STELARA
> Placebo
> 45 mg
> 90 mg
> Placebo
> 45 mg
> 90 mg
> Subjects randomized
> 255
> 255
> 256
> 410
> 409
> 411
> PASI 75 response<sup>a</sup>
> ≤100 kg
> 4% 
> 6/166
> 74% 
> 124/168
> 65% 
> 107/164
> 4% 
> 12/290
> 73% 
> 218/297
> 78% 
> 225/289
> >100 kg
> 2% 
> 2/89
> 54% 
> 47/87
> 68% 
> 63/92
> 3% 
> 3/120
> 49% 
> 55/112
> 71% 
> 86/121
> PGA of Cleared or 
> Minimal<sup>a</sup>
> ≤100 kg
> 4% 
> 7/166
> 64% 
> 108/168
> 63% 
> 103/164
> 5% 
> 14/290
> 74% 
> 220/297
> 75% 
> 216/289
> >100 kg
> 3% 
> 3/89
> 49% 
> 43/87
> 58% 
> 53/92
> 3% 
> 4/120
> 51% 
> 57/112
> 69% 
> 84/121
> <sup>a</sup> Subjects were dosed with trial medication at Weeks 0 and 4.”

Source: [STELARA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=8)

Note: Table 13 columns are placebo, STELARA 45 mg, and STELARA 90 mg for each trial.

## Maintenance of response

<a id="stelara-stopping-after-response"></a>

### What happens when Stelara is stopped after a response in plaque psoriasis?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “Subjects in Ps STUDY 1 who were PASI 75 responders at both Weeks 28 and 40 
> were re-randomized at Week 40 to either continued dosing of STELARA (STELARA 
> at Week 40) or to withdrawal of therapy (placebo at Week 40). At Week 52, 
> 89% (144/162) of subjects re-randomized to STELARA treatment were PASI 75 
> responders compared with 63% (100/159) of subjects re-randomized to placebo 
> (treatment withdrawal after Week 28 dose). The median time to loss of PASI 75 
> response among the subjects randomized to treatment withdrawal was 16 weeks.”

Source: [STELARA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=8)

## Pediatric efficacy

<a id="stelara-pediatric-efficacy"></a>

### How effective is Stelara for plaque psoriasis in children 12 and older?

Applies to: Pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “A multicenter, randomized, double blind, placebo-controlled trial (Ps STUDY 3) 
> enrolled 110 pediatric subjects 12 years of age and older with a minimum BSA 
> involvement of 10%, a PASI score greater than or equal to 12, and a PGA score 
> greater than or equal to 3, who were candidates for phototherapy or systemic 
> therapy and whose disease was inadequately controlled by topical therapy.”

Source: [STELARA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=8)

> “The endpoints were the proportion of subjects who achieved a PGA score of 
> cleared (0) or minimal (1), PASI 75, and PASI 90 at Week 12. Subjects were followed 
> for up to 60 weeks following first administration of trial agent.”

Source: [STELARA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=8)

> “Table 14: Efficacy Results at Week 12 in Pediatric Subjects 12 Years of Age and 
> Older with Plaque Psoriasis in Ps STUDY 3
> Ps STUDY 3
> Placebo
> n (%)
> STELARA<sup>a</sup>
> n (%)
> N
> 37
> 36
> PGA
> PGA of Cleared (0) or Minimal (1)
> 2 (5.4%)
> 25 (69.4%)
> PASI
> PASI 75 responders
> 4 (10.8%)
> 29 (80.6%)
> PASI 90 responders
> 2 (5.4%)
> 22 (61.1%)
> <sup>a</sup> Using the weight-based dosage regimen specified in Table 1 and Table 2.”

Source: [STELARA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=8)

## Related pages
- [Medical information: Stelara (ustekinumab): Plaque psoriasis](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/pharmacology)
- [Real-world evidence](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/storage-and-supply)
